Major Retailers Pull J & J Baby Powder After FDA Finds Asbestos

Major retailers have stopped selling the 22-ounce bottles of Johnson &Johnson baby powder after last week’s announcement that the U.S. Food and Drug Administration found traces of asbestos in one of the containers. Exposure to asbestos, a naturally occurring mineral and known carcinogen, is the primary cause of malignant mesothelioma, a rare and aggressive cancer with no definitive cure. Walmart, CVS Pharmacy and Rite Aid were among the many retailers that have pulled the product from shelves as part of the voluntary recall. “We always put customer safety first and foremost,” Chris Savarese, Rite Aid spokesman told The Mesothelioma Center at Asbestos.com. “Rite Aid informed all stores to pull all products from the shelves. We’ve also applied a point-of-sale system block for this product, to prevent it from being sold.” All three retailers have continued selling the product in other size containers. A Walmart spokesperson told The Mesothelioma Center at Asbestos.com it pulled only the containers that were part of the 33,000-bottle batch being recalled. Johnson &Johnson announced the voluntary recall of its iconic baby powder on October 18 after testing by the FDA found traces of asbestos in a bottle purchased recently from an online retailer. The company said that it was working closely with federal authorities to determine the validity of the test results and the integrity of the tested sample. FDA testing indicated sub-trace levels...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Conditions:   Advanced Solid Tumor;   MSI-H/dMMR Tumors;   Cutaneous Squamous Cell Carcinoma;   Urothelial Carcinoma;   Cervical Cancer;   HepatoCellular Carcinoma;   Esophageal Squamous Cell Carcinoma;   Merkel Cell Carcinoma;   Small-cell Lung Cancer;   Mesothelioma;   PD-L1 Ampli fied Tumor (9p24.1);   Nasopharyngeal Carcinoma Intervention:   Drug: INCB099280 Sponsor:   Incyte Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ONCOS-102, a promising immunotherapy vaccine, is moving closer to becoming a part of future first-line treatment for mesothelioma. Early clinical trial results announced this week show safety and efficacy when the vaccine is used in combination with standard-of-care chemotherapy for patients with inoperable pleural mesothelioma. Targovax, a Scandinavian pharmaceutical company developing the drug, is moving forward with another study combining ONCOS-102 with a checkpoint inhibitor drug such as Keytruda (pembrolizumab) or Opdivo (nivolumab), along with chemotherapy. “We have seen enough data at this point to be going ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer of the pleural surface associated with asbestos exposure. The median survival of MPM patients is a mere 8–14 months, and there are few biomarkers and no cure available. It is hoped that, eventually, the incidence of MPM will drop and remain low and constant, given that most nations have banned the use of asbestos, but in the meantime, the incidence in Europe is still growing. The exact molecular mechanisms that explain the carcinogenicity of asbestos are not known. Standard therapeutic strategies for MPM include surgery, often coupled with chemotherapy...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
AbstractActivated cap-dependent translation promotes cancer by stimulating translation of mRNAs encoding malignancy-promoting proteins. The nucleoside monophosphate Protide, 4Ei-10, undergoes intracellular uptake and conversion by Hint1 to form 7-Cl-Ph-Ethyl-GMP. 7-Cl-Ph-Ethyl-GMP is an analog of cap and inhibits protein translation by binding and sequestering eIF4E thus blocking eIF4E from binding to the mRNA cap. The effects of inhibiting translation initiation by disruption of the eIF4F complex with 4Ei-10 were examined in malignant mesothelioma (MM). In a cell-free assay system, formation of the eIF4F complex was disab...
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Conditions:   Thyroid;   Renal Cell Carcinoma;   Non Small Cell Lung Cancer;   Small-cell Lung Cancer;   Bladder Cancer;   Melanoma;   Merkel Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Microsatellite Instability High;   Triple Negative Breast Cancer;   Mesothelioma;   Thym ic Cancer;   Cervical Cancer;   Biliary Tract Cancer;   Hepatocellular Carcinoma;   Ovarian Cancer;   Gastric Cancer;   Head ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
A team of experts from eight different federal agencies has presented the U.S. Food and Drug Administration with preliminary recommendations to standardize the testing of talc for the presence of asbestos and other potentially harmful mineral products. The recommendations, some of which reject long-held talc industry positions, are designed to end the discrepancies in analysis of whether talc products are contaminated with cancer-causing substances. Preliminary recommendations will be part of the FDA’s public meeting on Feb. 4 to discuss and obtain scientific information on testing for asbestos in talc-based products...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conditions:   Thyroid;   Renal Cell Carcinoma;   Non Small Cell Lung Cancer;   Small-cell Lung Cancer;   Bladder Cancer;   Melanoma;   Merkel Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Microsatellite Instability High;   Triple Negative Breast Cancer;   Mesothelioma;   Thym ic Cancer;   Cervical Cancer;   Biliary Tract Cancer;   Hepatocellular Carcinoma;   Ovarian Cancer;   Gastric Cancer;   Head ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Researchers in Spain have discovered a drug combination showing potential in treating the most difficult-to-treat type of malignant mesothelioma. Selumetinib and AZD8186, already being studied separately in clinical trials for other cancers, displayed efficacy when used in combination on mesothelioma of the sarcomatoid cell type. Researchers at the Spanish National Cancer Research Centre made the discovery during their study using mice models and human tumor cells in the laboratory. “The findings, we hope, are relevant,” Dr. Paco Real, who led the study, told The Mesothelioma Center at Asbestos.com. “We d...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
An international research team has identified a novel molecular target with potential to significantly improve future treatment of malignant pleural mesothelioma. The recent findings could lead to a drug that targets key genetic inhibitors often preventing a patient’s own immune system from suppressing mesothelioma tumor growth. Dr. Antonio Giordano, part of the collaborative research team, said the goal is reducing mesothelioma mortality with a combinational therapy that includes this new target. “These findings help us define molecular mechanisms that may be key to mesothelioma aggressiveness and progression,...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Background: Pemetrexed is an antifolate cytostatic drug that targets multiple enzymes involved in folate biosynthesis and is indicated for treatment of non–small-cell lung cancer and malignant pleural mesothelioma. As evidence for an exposure–response/toxicity relationship is accumulating, dose individualization using therapeutic drug monitoring may be a feasible strategy to optimize treatment. The purpose of this study was to develop a simple, sensitive, high-performance liquid chromatography method with UV detection for quantification of pemetrexed levels in human plasma. Method: The method involves a si...
Source: Therapeutic Drug Monitoring - Category: Drugs & Pharmacology Tags: Short Communication Source Type: research
More News: Asbestosis | Babies | Cancer | Cancer & Oncology | Environmental Health | Food and Drug Administration (FDA) | Lawsuits | Learning | Legislation | Men | Mesothelioma | Minerals | Study | Universities | Universities & Medical Training | USA Health